Market revenue in 2023 | USD 758.3 million |
Market revenue in 2030 | USD 2,877.2 million |
Growth rate | 21% (CAGR from 2023 to 2030) |
Largest segment | Gmp grade |
Fastest growing segment | GMP Grade |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | R&D Grade, GMP Grade |
Key market players worldwide | Charles River Laboratories International Inc, Danaher Corp, Kaneka Corp, Eurofins Scientific SE, Lonza Group Ltd, Akron Biotechnology, Luminous BioSciences, Lonza Group Ltd ADR, Cell & Gene Therapy, Nature Technology, VGXI |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to plasmid dna manufacturing market will help companies and investors design strategic landscapes.
Gmp grade was the largest segment with a revenue share of 85.89% in 2023. Horizon Databook has segmented the North America plasmid dna manufacturing market based on r&d grade, gmp grade covering the revenue growth of each sub-segment from 2018 to 2030.
North America dominated the plasmid DNA manufacturing market in 2021 with the largest revenue share. This can be attributed to the growing engagement of companies in research and product development in gene & cell therapy coupled with a substantial number of contract development organizations in the region.
Furthermore, considering factors such as presence of a substantial number of biopharma companies and strong regulatory framework for promoting the development of cellular therapy in the region, several sponsors & government agencies are making major investments.
The partnership will leverage Charles River’s leading expertise in plasmid DNA manufacturing, specifically high-quality plasmid, which combines significant features of Good Manufacturing Practice (GMP) manufacturing with quick turnaround times to fast-track the timeline to clinic.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America plasmid dna manufacturing market , including forecasts for subscribers. This continent databook contains high-level insights into North America plasmid dna manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account